https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2024-11-14 18:16:202024-11-14 18:17:05ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2024-10-21 10:19:472024-10-21 10:22:593B Pharmaceuticals Announces Option and Asset Purchase Agreement with Novartis for PSMA Radioligand Therapy Program
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2023-09-20 11:45:522023-09-21 11:46:21RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2023-04-24 11:43:472023-04-24 11:46:523B Pharmaceuticals enters into a Global Exclusive Licensing Agreement for its FAP-Targeting Peptide Technology
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00Jan Michelhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngJan Michel2022-12-22 17:20:342022-12-22 17:21:513BP company statement re recent events involving Clovis Oncology and FAP-2286
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2022-06-10 10:35:482022-06-13 10:39:593B Pharmaceuticals hosts industry symposium on radiopharmaceutical innovation alliances and supports the 6th Theranostic World Congress
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2020-03-25 11:10:502020-05-12 16:40:50Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2019-09-23 12:31:552019-10-11 15:44:33Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
